Clinical Pipeline

Product BR PC phaseⅠ phaseⅡ phaseⅢ
NC-6004
Cisplatin micelle
Pancreatic cancer(Japan/Asia)
Combination therapy with Gemcitabin
Co-Development
Partner:Orient Europharma(Taiwan)
NSCL, Bladder, Biliary tract(USA/EU)
Combination therapy with Gemcitabin
In-House Development
FDA Orphan drug designation
(Biliary tract cancer)
Head and Neck cancer(USA/EU/Taiwan)
Combination therapy with Kyet ruda®
Co-Development
Partner:Orient Europharma(Taiwan)
VB-111
(In-Licensed)
Non-replicating Adeno 5 vectors
Planning domestic
development
In-House Development
In-Licensed from VBL(Aria:Japan)
Partner:VBL(Israel)
rGBM/Ovarian cancer etc.
Operation byVBL(USA etc.)
ENT product
ENT(Japan)
Co-Development
Partner:CEOLIA PHARMA(Japan)
NC-6300
Epirubicin micelle
Soft tissue sarcoma(USA)
Combination therapy with Oralazumab
In-House Development
FDA Orphan drug designation
NC-4016
Dach-platinum micelle
Solid cancer(USA)
In-House Development
NK105
(Out-Licensed)
Paclitaxel micelle
Breast cancer(Japan/Asia)
Gastric cancer(Japan)
Out-licensed to Nippon Kayaku(Aria:Japan/Asia)
Partner:Nippon Kayaku(Japan)